Application Evaluation of High-Flow Humidified Oxygen in Patients with Respiratory Failure after General Anesthesia Extubation for Multiple Injuries

LINC00312 Inhibits Lung Cancer Progression through the miR-3175/SEMA6A Axis

This study aims to clarify molecular mechanisms and tumor-associated functions of LINC00312 in lung cancer. GEO database was used to acquire lung cancer-related expression microarrays. Then, relevant databases were applied to predict the downstream miRNA for LINC00312 and the target mRNA for the potential miRNA, with their associations deeply confirmed through dual-luciferase and RIP assays. The expression levels of epithelial-mesenchymal transition -related proteins (N-cadherin, Vimentin, MMP-2, and MMP-9) were examined by Western blot. The proliferation, migration, and invasion were evaluated through in vitro experiments including CCK-8 and Transwell assays and further validated by nude mouse xenograft tumor experiment. LINC00312, serving as a tumor suppressor, was down-regulated in lung cancer cells. RIP assay proved that miR-3175 bound LINC00312 and SEMA6A. The dual-luciferase assay showed that miR-3175 specifically targeted SEMA6A, suppressing the expression of SEMA6A. Overexpressing LINC00312 remarkably inhibited the binding between miR-3175 and SEMA6A. Overexpressing miR-3175 or silencing SEMA6A could hamper the effects of LINC00312 on lung cancer cells. LINC00312 inhibits lung cancer occurrence and progression via the miR-3175/SEMA6A axis.

Retracted: Application Evaluation of High-Flow Humidified Oxygen in Patients with Respiratory Failure after General Anesthesia Extubation for Multiple Injuries

[This retracts the article DOI: 10.1155/2021/1387129.].

Therapeutic effects and the influence on serum inflammatory factors of high-flow nasal cannula oxygen therapy in senior patients with lower respiratory tract infections

BACKGROUND: Lower respiratory tract infection (LRTI) is a clinical multi-infectious disease caused by viral, bacterial, and other microbial infections. OBJECTIVE: The present study aims to explore the therapeutic effects of high-flow nasal cannula (HFNC) oxygen therapy and its influence on the serum levels of inflammatory factors in senior patients with LRTI. METHODS: In this randomized controlled trial, 84 senior patients with LRTI were enrolled between March 2017 and December 2019 and divided into the observation group and the control group according to the random number table method, with 42 cases in each group. Conventional nasal cannula (CNC) oxygen therapy was conducted in the control group and HFNC was conducted in the observation group. After 3 days of treatment, sputum properties, sputum volume, sputum viscosity, and sputum crust formation were recorded to determine the clinical efficacy. ELISA was performed to detect the serum levels of tumor necrosis factor alpha (TNF-α) and interlukein (IL)-8 before and after treatment. RESULTS: The total efficacy in the observation group was 92.86%, which was higher than in the control group (73.81%) (P< 0.05). Three days after treatment, the percentage of grade I sputum in the observation group (73.81%) was higher than in the control group (40.48%). Moreover, the percentage of grade II sputum (23.81%), the percentage of grade III sputum (2.38%), together with the sputum crust formation rate in the observation group (4.76%) were all lower than in the control group (45.24, 14.28, and 26.19%, respectively) (P< 0.05). Three days after treatment, the levels of IL-8 (0.21 ± 0.03 pg/L) and TNF-α (1.27 ± 0.14 ng/L) in the observation group were lower than in the control group (0.30 ± 0.04 pg/L, and 1.49 ± 0.18 ng/L) (t= 6.525, 11.665, 6.252, respectively; P< 0.05). CONCLUSION: The application of HFNC in senior patients with LRTI could improve respiratory humidification, reduce the number of sputum aspirations, and improve anti-inflammatory effects. It is worthy of application in elderly patients with LRTI.